• 2024 AAM Generic & Biosimilar Medicines Savings Report
    2024 U.S. Generic & Biosimilar Medicines Savings Report
    Generic and biosimilar medicines saved $445 billion in 2023. Representing 90 percent of prescriptions filled but only 13 percent of spending, generics and biosimilars are an integral part of the U.S. healthcare system. However, the sustainability of this industry remains fragile.
  • Hatch-Waxman 40 Years
    AAM White Paper: Hatch-Waxman Turns 40
    “Since the introduction of this law, we have all seen incredible savings. But even as we celebrate the success of forty years of Hatch-Waxman, those savings, the increased patient access, and a model of generic adoption that leads the world, are at risk.” —David Gaugh, Interim President & CEO, AAM.
  • Access! AAM Annual Meeting 2025
    Join Us at Access! 2025
    AAM’s annual meeting unites policymakers, influential speakers, and industry leaders to shape the future of generics and biosimilars. Engage in discussions about the business, breakthroughs, and politics that drive our industry. This is your chance to hear from world-renowned speakers and gain insights into the future of our field. February 3–5, 2025, at Amelia Island, FL.
  • Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
    Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers.

Our Brands and Campaigns

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.